Intellectual Product – Page 5

Sanofi Contributes to Report Emphasizing Importance of Sustainably Paid Community Health Workers

2 months ago talkbio0Tagged Advocacy, CHW Access Act, Community Health Workers, digital infrastructure, Health Equity, National Association of, Policy, sanofi, sustainability

Sanofi; community health workers; sustainability; health equity; National Association of Community Health Workers; policy advocacy; digital infrastructure; CHW Access Act

CDC Staff and Medical Organization Liaisons Barred from New ACIP Covid-19 Working Group

2 months ago talkbio0Tagged ACIP, Centers for Disease Control and Prevention (U.S.), COVID19 (disease), Jr., medical groups, Policy, Robert F. Kennedy, staff exclusion, Vaccines, Working Group

CDC; ACIP; Covid-19; working group; staff exclusion; medical groups barred; vaccine policy; Robert F. Kennedy Jr.

Resilience Through Reinvention: How Pharma is Navigating Uncertainty During Turbulent Times

2 months ago talkbio0Tagged adaptation, Apis (invertebrate), Clinical Trials, drug price, Generalized, Investments, manufacturing uncertainty, Market, Pharma, Policy, regulatory environment, Reinvention, resilience, strategic reserves, supply chain

pharma; resilience; reinvention; supply chain; manufacturing uncertainty; regulatory environment; global market adaptation; funding; investment; clinical trials; drug pricing policy; APIs; strategic reserves

Dynavax Highlights Comparable Efficacy and Improved Tolerability of Z-1018 Shingles Vaccine vs. Shingrix

2 months ago talkbio0Tagged aspects of adverse effects, Dynavax, Effectiveness, Herpes zoster disease, Immunogenicity (package insert), Shingrix, Vaccines, Z-1018

Dynavax; Z-1018; shingles vaccine; Shingrix; vaccine efficacy; side effects; Phase 1/2 trial; immunogenicity

Trump’s Most Favored Nation Policy and EU Generics: Recent Developments

2 months ago talkbio0Tagged drug price, EU, generics, Nation, Pharma, Policy, tariffs, Transplant Registry Unified Management Program

Trump; Most Favored Nation policy; EU generics; drug pricing; tariffs; pharma

Sarepta Extends $700M Debt to 2030, Adds Private Placement Amid Elevidys Uncertainty

2 months ago talkbio0Tagged Biopharma, convertible, debt maturity extension, ELEVIDYS, financial strategy, Note (document), private placement

Sarepta Therapeutics; debt maturity extension; convertible notes; private placement; Elevidys; financial strategy; biopharma

American Academy of Pediatrics Breaks with RFK Jr., CDC on COVID Vaccines for Kids

2 months ago talkbio0Tagged Academy of Pediatrics, antiarrhythmic peptide, Centers for Disease Control and Prevention (U.S.), Child, COVID19 (disease), Immunization, Pediatric brand name, Policy, public health guidance, Robert F. Kennedy, Vaccines

American Academy of Pediatrics; AAP; COVID-19 vaccine; children; CDC; Robert F. Kennedy Jr.; pediatric immunizations; public health guidance; vaccine policy

Tariffs and MFN Policy Power a Broad, Confusing Pharma War

2 months ago talkbio0Tagged Drug Industry, drug manufacturing, Drug Prescriptions, Medicaid, MFN, Nation, onshoring, pharma innovation, Policy, Trump administration

tariffs; Most Favored Nation (MFN) policy; prescription drug pricing; pharmaceutical industry; Trump administration; drug manufacturing; onshoring; Medicaid; pharma innovation

Federal Appeals Court Overturns FDA Rejection of Vanda’s Hetlioz for Jet Lag Disorder

2 months ago talkbio0Tagged Clinical Trials, Evidence, Federal Appeals Court, Hetlioz, jet lag disorder, New Drug Application, regulatory law, sNDA, United States Food and Drug Administration, Vanda Pharmaceuticals

Vanda Pharmaceuticals; Hetlioz; FDA; jet lag disorder; Federal Appeals Court; supplemental New Drug Application (sNDA); regulatory law; clinical trial evidence

Reunion Psychedelic Therapy Advances to Pivotal Trials after Postpartum Depression Success

2 months ago talkbio0Tagged Clinical Trials, Depression, Postpartum, Montgomery-Åsberg Depression Rating Scale, Montgomery-Asberg Depression Rating Scale Questionnaire, Neuroscience discipline, Phase 2 Clinical Trials, Phase 3 Clinical Trials, psychedelic therapy, RE104, RECONNECT, remission rates, Reunion

Reunion Neuroscience; RE104; psychedelic therapy; postpartum depression (PPD); Phase II trial; Phase III trial; RECONNECT trial; clinical trial results; Montgomery-Åsberg Depression Rating Scale (MADRS); remission rates